Prevalence and Clinical Significance of Anti-DFS70 in Antinuclear Antibody (ANA)–positive Patients Undergoing Routine ANA Testing in a New Zealand Public Hospital

Article Figures & Data

Download figure
Open in new tab
Download powerpoint
Figure 1.
(A) Proposed new ANA result interpretation algorithm that includes the anti-DFS70 results. (B) Proposed new ANA test algorithm considering anti-DFS70 antibodies on all ANA-positive samples. ANA: antinuclear antibodies; DFS: dense fine speckled; ENA: extractable nuclear antigen; SARD: systemic autoimmune rheumatic diseases.

Table 1.

Test results and clinical details of anti-DFS70–positive patients.

Sample	ANA-2 IIF Pattern Operator Interpretation LIU (Cutoff = 48)	ANA ELISA/ANA (Cutoff = 1.0)	Anti-DFS70 CIA/CU (Cutoff = 20)	Clinical Details
1	Centromere/homogenous (232)	Positive (5.21)	33	Non-SARD. Lung cancer, pulmonary sarcoidosis. History of anticentromere antibodies.
2	Speckled (438)	Positive (2.75)	> 450	Non-SARD. Recurrent blistering. Previous ANA-positive (homogenous) and anti-Scl-70.
3	Homogenous (179)	Positive (2.54)	76	Non-SARD. Ulcerative colitis. No ANA test history.
4	Centromere (305)	Positive (2.91)	262	Non-SARD. Sudden loss of sensation, facial nerve distribution. No ANA test history.
5	Unrecognised/negative (24)	Positive (1.06)	119	Non-SARD. Primary Raynaud, Previous ANA-positive (homogenous).
6	Homogenous (215)	Positive (3.5)	52	Non-SARD. Epilepsy, 2× miscarriages. Positive anticardiolipin, positive lupus anticoagulant. Previous ANA-positive (speckled), ENA-negative.
7	DFS (146)	Positive (1.01)	414	Non-SARD. No ANA test history.
8	Homogenous (107)	Positive (1.98)	137	SARD. SLE monitoring. Previous ANA-positive (homogenous).

DFS: dense fine speckled; ANA: antinuclear antibodies; LIU: light intensity units; CIA: chemiluminescence immunoassay; CU: chemiluminescent units; SARD: systemic autoimmune rheumatic diseases; ENA: extractable nuclear antigen; SLE: systemic lupus erythematosus.